Execution is improving, debt still matters
- Astrana makes most of its money from capitated payments, fixed payments to manage care for members.
- About 78% of revenue came from full-risk arrangements as of Q2 2025, up from 60% a year earlier.
- Q1 2026 revenue was $965.1 million, up 56% year over year, and adjusted EBITDA rose 82%.
- The new segment view shows Care Enablement as a smaller but high-profit piece of the story.
- The Prospect deal is on track so far, but full integration and medical cost control remain key tests.
A better view into the engine
Astrana had a strong start to 2026. Management reported Q1 2026 revenue of $965.1 million, up 56% year over year, and adjusted EBITDA of $66.3 million, up 82%. Free cash flow was just over $64 million in the quarter. That supports the bull case that Astrana can grow while keeping medical costs under control.
The biggest new detail is the reporting change. Astrana now shows Care Partners, Care Delivery, and Care Enablement as separate segments. That matters because Care Enablement produced $20.2 million of operating income on $87.7 million of revenue in Q1 2026. This makes the technology and management services business easier to see.
The balance sheet is improving faster than expected. Net leverage fell to about 2.3x on a pro forma trailing 12-month basis, and management now targets at or below 2.0x by year-end. That helps, but financial health is still a weak spot. Debt is lower risk than it was after the Prospect deal, not a solved issue.
The bear case is now more focused. If medical costs rise in the second half of 2026, if Prospect integration stumbles, or if the company misses its 2026 guidance, the stock could be hit hard. The setup is better, but the market is likely giving management less room to miss.
Paid to manage total care costs
Astrana runs a value-based care model. In plain English, it works with doctors and health plans, then gets paid to manage the full care needs of groups of patients. The main revenue source is capitated payments from Medicare, Medicaid, and commercial payers. Capitated means Astrana gets a set payment per member, then tries to deliver good care for less than that amount.
The model can be powerful when it works. Better care coordination, data, and doctor support can lower avoidable hospital stays and other costly care. Astrana keeps more profit if medical costs come in below what it planned.
The same model can hurt fast when it goes wrong. In full-risk contracts, Astrana is responsible for more of the medical bill. As of Q2 2025, about 78% of revenue came from full-risk arrangements, compared with 60% a year earlier. That shift can raise margins, but it also raises the cost-control test.
The Prospect acquisition made Astrana much larger. It also made integration more important. Management says provider retention was above 99% in Q1 2026 and synergies are tracking toward the high end of the $12 million to $15 million target. Investors still need proof that this holds after the full platform onboarding is done.
Doctors, clinics, and the platform between them
Care Partners
This is the largest segment. It partners with physician groups in value-based arrangements and generated $909.7 million of revenue in Q1 2026.
Care Enablement
This segment provides management services and technology to internal and external doctor groups. In Q1 2026, it generated $87.7 million of revenue and $20.2 million of operating income.
Care Delivery
This includes Astrana's primary, multi-specialty, and ancillary care entities. It produced $85.1 million of revenue in Q1 2026, but still posted a $3.0 million operating loss as it scales.
Full-risk contracts
Astrana is shifting more revenue into full-risk arrangements. These contracts can improve profit if medical costs stay controlled, but they make cost misses more painful.
Jointly branded clinics
Astrana is also building and operating clinics with major payers such as Anthem Blue Cross. This gives the company a more direct role in patient care, not only provider enablement.
Care Partners is still the core
Segment shares are based on reported segment revenue for the quarter ended March 31, 2026. Care Partners is the clear revenue base, while Care Enablement is smaller but showed much higher operating income relative to revenue.
Where the thesis can break
Medical costs rise faster than planned
High impact · Medium oddsAstrana takes meaningful risk for patient medical costs. Q1 2026 trends were well controlled, but a spike in utilization or severity would pressure margins. This matters more as full-risk contracts become a larger part of revenue.
Prospect integration slows down
High impact · Medium oddsThe Prospect acquisition is large and complex. Management says integration is on track, provider retention was above 99% in Q1 2026, and synergies are tracking toward the high end of $12 million to $15 million. The risk is that final platform onboarding takes longer or disrupts operations.
Guidance becomes a high bar
High impact · Medium oddsManagement guided 2026 revenue to $4.0 billion to $4.2 billion and adjusted EBITDA to $240 million to $260 million. Strong Q1 results support that plan, but also raise expectations. A small miss could matter if investors view the stock as an execution story.
Debt reduction stalls
Medium impact · Medium oddsAstrana has delevered faster than planned, reaching about 2.3x net leverage on a pro forma trailing 12-month basis in Q1 2026. Management now targets at or below 2.0x by year-end. If free cash flow weakens, the balance sheet could again limit flexibility.
Care Delivery losses persist
Medium impact · Medium oddsCare Delivery is growing, but it lost $3.0 million at the operating income line in Q1 2026. That may be acceptable while the clinic footprint scales. It becomes a problem if losses do not narrow as revenue grows.
In one breath
What does Astrana Health do?
Astrana helps physician groups run value-based care programs. It provides technology, clinical support, management services, and in some cases direct care through clinics.
Why does full-risk revenue matter for Astrana?
Full-risk contracts can raise profit because Astrana keeps more upside when care costs are lower than planned. They also raise risk because Astrana must absorb more of the downside when medical costs run high.
What changed in Astrana's latest reporting?
Astrana now reports three segments: Care Partners, Care Delivery, and Care Enablement. This gives investors a clearer look at the high-profit Care Enablement segment.
What is the main thing to watch in 2026?
The key test is whether Astrana can hit its 2026 guidance while finishing the Prospect integration. Medical cost trends and net leverage are the clearest signals.